CAMP4 Therapeutics Corporation Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
CAMP4 Therapeutics Corporation (CAMP) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$16.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-05
- CAMP4 Therapeutics Corporation effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$16.89M.
- CAMP4 Therapeutics Corporation effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$10.88M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$16.89M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$10.88M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |